Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

Although immunotherapy can offer profound clinical benefit for patients with a variety of difficult-to-treat cancers, many tumors either do not respond to upfront treatment with immune checkpoint inhibitors (ICIs) or progressive/recurrent disease occurs after an interval of initial control. Improved...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizvi, Naiyer, Ademuyiwa, Foluso O, Cao, Z Alexander, Chen, Helen X, Ferris, Robert L, Goldberg, Sarah B, Hellmann, Matthew D, Mehra, Ranee, Rhee, Ina, Park, Jong Chul, Kluger, Harriet, Tawbi, Hussein, Sullivan, Ryan J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016262/
https://www.ncbi.nlm.nih.gov/pubmed/36918220
http://dx.doi.org/10.1136/jitc-2022-005920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016262/
https://www.ncbi.nlm.nih.gov/pubmed/36918220
http://dx.doi.org/10.1136/jitc-2022-005920

Ejemplares similares